for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

KPC Pharmaceuticals Inc

600422.SS

Latest Trade

11.58CNY

Change

-0.05(-0.43%)

Volume

13,029,107

Today's Range

11.48

 - 

11.70

52 Week Range

5.95

 - 

15.50

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
11.63
Open
11.60
Volume
13,029,107
3M AVG Volume
813.61
Today's High
11.70
Today's Low
11.48
52 Week High
15.50
52 Week Low
5.95
Shares Out (MIL)
761.22
Market Cap (MIL)
8,852.96
Forward P/E
20.77
Dividend (Yield %)
0.86

Latest Developments

More

KPC Pharmaceuticals Says 2018 Net Profit Up 1.65 Percent Y/Y

KPC Pharmaceuticals Says Board Elects Wang Siyang As Chairman

KPC Pharmaceuticals Says Lock-Up Period For 106.4 Million Shares To End

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About KPC Pharmaceuticals Inc

KPC Pharmaceuticals, Inc. is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company's main products include natural herbal medicines, traditional Chinese medicines and chemical synthetic drugs, such as central nervous system drugs, cardiovascular and cerebrovascular drugs, anti-parasitic drugs, anti-microbial drugs, anti-gout drugs, hormones and endocrine drugs, hemorrhoids medicines and anti-inflammatory drugs, among others. The Company is also engaged in the production of health products and provision of medical services.

Industry

Biotechnology & Drugs

Contact Info

No. 166

Keyi Road, High-tech Development Zone

+86.871.68324311

http://www.kpc.com.cn

Executive Leadership

Xianggang Zhong

President

C.H. Lin

Vice Chairman of the Board

Shaoquan Wang

Chief Financial Officer

Chaoneng Xu

Vice President, Secretary of the Board

Zhongzhan Lin

Vice President

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

5.1K

2017

5.9K

2018

7.1K

2019(E)

7.9K
EPS (CNY)

2016

0.516

2017

0.419

2018

0.440

2019(E)

0.560
Price To Earnings (TTM)
22.85
Price To Sales (TTM)
1.18
Price To Book (MRQ)
2.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
22.88
LT Debt To Equity (MRQ)
2.64
Return on Investment (TTM)
9.13
Return on Equity (TTM)
5.80

Latest News

BRIEF-KPC Pharmaceuticals Plans Share BuyBack Worth 200-500 Million Yuan Within Six Months

* SAYS IT PLANS TO BUY BACK COMPANY SHARES WORTH 200-500 MILLION YUAN AT NO HIGHER THAN 11 YUAN ($1.73) PER SHARE WITHIN SIX MONTHS Source text in Chinese: http://bit.ly/2CcjHQG Further company coverage: ($1 = 6.3591 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-KPC Pharmaceuticals to invest 10 mln yuan to set up medicine unit in Yichun

* Says it plans to invest 10 million yuan to set up a Yichun-based wholly owned medicine unit

BRIEF-KPC Pharmaceuticals names president

KPC Pharmaceuticals Inc * Says it names Zhong Xianggang as president Source text in Chinese: https://goo.gl/RaLKZ4 Further company coverage: (Beijing Headline News)

REFILE-BRIEF-KPC Pharmaceuticals Says President Resigns Due To Personal Reasons

* SAYS PRESIDENT DAI XIAOCHANG RESIGNS DUE TO PERSONAL REASONS Source text in Chinese: http://bit.ly/2C21wh0 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-KPC Pharmaceuticals and unit passe review of high-tech enterprise recognition

* Says it and wholly owned Xishuangbanna medical unit passe review of high-tech enterprise recognition, to enjoy a tax preference of 15 percent for three years

BRIEF-KPC Pharmaceuticals unit to buy 60 pct stake in Dali-based pharma for 18 mln yuan

* Says its unit plans to use 18 million yuan to buy a 60 percent stake in a Dali-based pharmaceutical company

BRIEF-KPC Pharmaceuticals sells land action worth 19.6 mln yuan

* Says it sold land action worth 19.6 million yuan to a tourism land mineral reserve center

BRIEF-KPC pharmaceuticals' H1 net profit down 13.2 pct y/y

KPC Pharmaceuticals Inc * Says H1 net profit down 13.2 percent y/y Source text in Chinese: http://bit.ly/2uO26LD Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-KPC Pharmaceuticals's shareholder plans to unload up to 25 pct stake in co within six months

* Says shareholder Yuan Dongping plans to unload up to 25 percent stake in the co within six months

BRIEF-KPC Pharmaceuticals unit plans medical JV worth 10 mln yuan with partner

* Says its unit plans to use 8.2 million yuan to set up a medical JV with partner in Yuxi city

BRIEF-KPC Pharmaceuticals to use 31 mln yuan to set up health industry investment JV with partners

* Says it plans to use 31 million yuan to set up a health industry investment JV in Kunming with partners

BRIEF-KPC Pharma to buy back shares in the company within six months

* Says it plans to buy back 8.0 million shares in the company at up to 16.22 yuan ($2.38) per share within six months

BRIEF-KPC Pharmaceuticals unit to buy 60 pct stake in Yunnan medical firm

* Says co's unit plans to use 31.0 million yuan to buy 60 percent stake in a Yunnan-based medical firm and will inject 6 million yuan in it after acquisition

BRIEF-KPC Pharmaceuticals to pay FY 2016 annual div on May 19

* Says it will pay cash dividend of 1.8 yuan per 10 shares (before tax) to shareholders of record on May 18, for FY 2016

BRIEF-KPC Pharmaceuticals unit receives CPQ from WHO for Artemether API

* Says its unit receives Confirmation of WHO Active Pharmaceutical Ingredient Prequalification for its Artemether API

BRIEF-KPC Pharmaceuticals to buy 60 pct stake in Yunnan firm for 21 mln yuan

* Says its wholly owned unit will buy 60 percent stake in a Yun'nan-based pharmaceuticals firm for 21 million yuan

BRIEF-KPC Pharmaceuticals to pay cash 1.8 yuan per 10 shares as FY 2016 div payment

* Says it plans to pay cash 1.8 yuan per 10 shares as FY 2016 div payment

BRIEF-KPC Pharmaceuticals' 2016 net profit down 3.2 pct

* Says 2016 net profit down 3.2 percent y/y at 407.3 million yuan ($59.17 million)

BRIEF-KPC Pharma to signs MOU with Swiss firm Wockhardt on sales of insulin related products in China

* Says it plans to signs MOU with Switzerland's Wockhardt on sales of insulin-related products in China

BRIEF-KPC Pharmaceuticals plans 20 mln yuan investment in healthcare investment partnership

* Says it plans to invest 20 million yuan in Chengdu-based healthcare investment partnership

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up